An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome
- 1 April 1999
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 13 (5) , 565-573
- https://doi.org/10.1097/00002030-199904010-00005
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology studyAIDS, 1999
- HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trialThe Lancet, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individualsThe Lancet, 1996
- Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDSNew England Journal of Medicine, 1996
- Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infectionThe Lancet, 1994
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992
- Flexible regression models with cubic splinesStatistics in Medicine, 1989
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989